2022年

1.Seya, T., and M. Matsumoto. 2020. Seya, T., and M. Matsumoto. 2022. Toward developing harmless vaccines: ARNAX for prophylactic adjuvant. Cells.https://doi.org/10.3390/cells11244006

2.Iwata-Yoshikawa, N., N. Nagata, H. Takaki, M. Matsumoto, T. Suzuki, H. Hasegawa, T. Seya. 2022. Prophylactic vaccine targeting Toll-like receptor 3 (TLR3) on dendritic cells ameliorates eosinophilic pneumonia in a mouse SARS-CoV infection model. ImmunoHorizons. 6: 275-282 https://doi.org/10.4049/immunohorizons.2200020

2020年

  1. M. Matsumoto, Y. Takeda and T. Seya 2020. Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2020.1749260

2019年

  1. Yoshida, S., H. Shime, M. Matsumoto, M. Kasahara, and T. Seya. 2019. An anti-oxidative amino acid L-ergothioneine modulates tumor microenvironment to facilitate adjuvant vaccine immunotherapy.Front Immunol.10: 671.
  2. Fukui-Miyazaki, A., U. Tamaru, T. Hirahashi, Y. Imai, S. Yoshida, M. Matsumoto, and T. Seya. 2019. A hot-water-extract of Spirulina platensis enhances spontaneous cytotoxic T cell activation and tumor regression in mouse tumor models.Innate Immunity.(submitted)
  3. Mugikura, K., G. Wang, M. Okamoto, T. Kouwaki, H. Takaki, K. Funami, T. Seya, and H. Oshiumi. 2019. Cytoplasmic double-stranded RNA induces the expression of Oct3/4 and NANOG mRNA in human differentiated cells.J Biol Chem.(submitted)
  4. Seya, T., Y. Takeda, and M. Matsumoto. 2019. Design of the TLR3-specific adjuvant for therapeutic vaccine immunotherapy.Adv. Drug Deliv. Rev.60: (in press)

2018年

  1. Takaki, H., S. Kure, H. Oshiumi, H. Y. Sakoda, T. Suzuki, A. Ainai, H. Hasegawa, M. Matsumoto, and T. Seya. 2018. Toll-like receptor 3 in nasal CD103+ dendritic cells is involved in immunoglobulin A production. Mucosal Immunol. 11: 82-96.
  2. Yoshida S, H. Shime, Y. Takeda, N. Jim-min, K. Takashima, M. Matsumoto, H. Shirato, M. Kasahara, T. Seya. 2018. Radiation-induced tumor regression is augmented by pre-TLR3 stimulation with polyIC in mouse models. Cancer Sci.109: 956-965.
  3. Nakamura H, Oku K, Ogata Y, Ohmura K, Yoshida Y, Kitano E, Fujieda Y, Kato M, Bohgaki T, Amengual O, Yasuda S, Fujimura Y, Seya T, Atsumi T. 2018. Alternative pathway activation due to low level of complement factor H in primary antiphospholipid syndrome.Thromb Res.164: 63-68
  4. Takeda, Y., M. Azuma, K. Funami, H. Shime, M. Matsumoto, and T. Seya. 2018. Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide.Front Immunol.9: 496.
  5. Takashima, K., H. Oshiumi, M. Matsumoto, and T. Seya. 2018. TICAM-1 is dispensable in STING-mediated innate immune responses in myeloid immune cells. Biochem Biophys Res Commun.499: 985-991.
  6. Takeda, Y., S. Yoshida, K. Takashima, N. Ishii-Mugikura, H. Shime, T. Seya, and M. Matsumoto. 2018. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.Cancer Sci.109: 2119-2129.
  7. Takeda, Y., M. Azuma, R. Hatsugai, Y Fujimoto, M. Hashimoto, K. Fukase, M. Matsumoto, and T. Seya. 2018. The second and third amino acids of Pam2 lipopeptides are key for the proliferation of cytotoxic T cells.Innate Immun.24: 323-331.
  8. Takeda, Y., H. Takaki, A. Miyazaki, S. Yoshida, M. Matsumoto, and T. Seya. 2018. Vaccine adjuvant ARNAX promotes mucosal IgA production in influenza HA vaccination.Biochem Biophys Res Commun.506: 1019-1025.
  9. Seya, T., Y. Takeda, K. Takashima, S. Yoshida, M. Azuma, and M. Matsumoto. 2018. Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.Proc Jpn Acad, Series B. 94: 153-160.
  10. Takaki, H., S. Ichimiya, M. Matsumoto, and T. Seya. 2018. Mucosal immune response in nasal-associated lymphoid tissue upon intranasal administration by adjuvants.J Innate Immun. 10: 515-521.
  11. Tatematsu, M., K. Funami, T. Seya, and M. Matsumoto. 2018. Extracellular RNA Sensing by Pattern Recognition Receptors.J Innate Immun.10: 398-406.

2017年

  1. Shime, H., M. Matsumoto, and T. Seya. 2017. Double-stranded RNA promotes CTL-independent tumor cytolysis supported by CD11b+Ly6G+ intratumor myeloid cells through the TICAM-1 signaling pathway.Cell Death Differ.24: 385-396.
  2. Shibata Y, Tokunaga F, Komatsu G, Gohda J, Saeki Y, Tanaka K, Takahashi H, Sawasaki T, Inoue S, Oshiumi H, Seya T, Nakano H, Tanaka Y, Iwai K, and Inoue J. 2017. HTLV-1 1 Tax Induces Formation of the Active Macromolecular IKK Complex by Generating Lys63- and Met1-Linked Hybrid Polyubiquitin Chains.PLoS Pathog.13: e1006162.
  3. Takashima, K., H. Oshiumi, M. Matsumoto, T. Seya. 2017. DNAJB1/HSP40 inhibits the MDA5-MAVS signaling in conjunction with HSP70. J Innate Immun.2018;10(1):44-55.
  4. Takeda, Y., K. Kataoka, J. Yamagishi, S. Ogawa, T. Seya, and M. Matsumoto. 2017. The TLR3-specific adjuvant relieves innate resistance to PD-L1 blockade without cytokine toxicity in tumor vaccine immunotherapy. Cell Rep.19(9):1874-1887.
  5. Shime, H., A. Maruyama, S. Yoshida, Y. Takeda, M. Matsumoto, and T. Seya. 2017. Toll-like receptor 2 ligand and interferon-γ synergistically enhance immunosuppressive activity of monocytic myeloid-derived suppressor cells. Oncoimmunol.7: e1373231.
  6. Kouwaki T., M. Matsumoto, T. Seya, and H. Oshiumi. 2017. Zyxin stabilizes RIG-I and MAVS interaction and promotes type I interferon expression. Sci Rep. 7: 11905.
  7. Ono J, Shime H, Takaki H, Takashima K, Funami K, Takeda Y, Yoshida S, Matsumoto M, and Seya T. 2017. The TLR3/TICAM-1 signal constitutively controls spontaneous polyposis through suppression of c-Myc in ApcMin/+ mice. J Biomed. Sci. 24: 79.
  8. Takaki, H., K. Takashima, H. Oshiumi, A. Ainai, T. Suzuki, H. Hasegawa, M. Matsumoto, and T. Seya. 2017. cGAMP promotes germinal center formation and production of IgA in nasal-associated lymphoid tissue. Med. Sci. 5: pil: E35.
  9. Oshiumi, H., T. Kouwaki, and T. Seya. 2017. Accessory factors of cytoplasmic viral RNA sensors required for antiviral innate immune response.Front Immunol. 7: 200
  10. Funami, K., M. Matsumoto, H. Oshiumi, F. Inagaki, and T. Seya. 2017. Functional interfaces between TICAM-2/TRAM and TICAM-1/TRIF in TLR4 signaling. Biochem Soc Trans. 45: 929-935.
  11. Takaki, H., H. Oshiumi, M. Shingai, M. Matsumoto, and T. Seya. 2017. Development of mouse models for analysis of human virus infections. Microbiol Immunol. 61: 107-113.
  12. Okamoto, M., H. Tsukamoto, T. Kouwaki, T. Seya, and H. Oshiumi. 2017. Recognition of viral RNA by pattern recognition receptors in the induction of innate immunity and excessive inflammation during respiratory viral infections. Viral Immunol. 30: 408-420.
  13. Matsumoto, M., Y. Takeda, M. Tatematsu, T. Seya. 2017. TLR3 signal in dendritic cells benefits cancer immunotherapy. Front Immunol. 8: 1897.

2016年

  1. Kasamatsu, J., M. G. Deng, T. Ebihara, M. Azuma, M. Matsumoto, and T. Seya. 2015. Genomic and expression analysis of murine paired triggering receptors expressed on myeloid cells in mouse. BMC Immunol. 17(1):9.
  2. Azuma, M., Y. Takeda, H.Nakajima, H. Sugiyama, T. Ebihara, H. Oshiumi. M. Matsumoto, and T. Seya. 2015. BATF3 fundamentally supports TLR3-derived IL-12 induction in CD8a+ dendritic cells, which promotes antitumor T cell responses by Poly(I:C).Oncoimmunol. 8:ell88244.
  3. Tatematsu, M., R. Yoshida, Y. Morioka, A. Watanabe, K. Saeki, T. Seya, and M. Matsumoto. 2016. Raftlin controls LPS-induced TLR4 internalization and TICAM-1-dependent signalling. J Immunol. 196(9): 3865-3876.
  4. Takaoka S., Y. Kamioka, K. Takakura, A. Baba, H. Shime, T. Seya, and M. Matsuda. 2016. In vivo imaging of TAK1 activation in PolyI:C-stimulated tumor cells. Cancer Sci. 107(5): 644-652.
  5. Funami, K., M. Matsumoto, M. Tatematsu, C. Obuse, and T. Seya. 2016. 14-3-3-zeta participates in TLR3-mediated TICAM-1 signal-platform formation.Molec Immunol. 73: 60-68.
  6. Yoshida, S. H. Shime, K. Funami, H. Takaki, M. Matsumoto, Tomiyama, Ishida, M. Kasahara, and T. Seya. 2016. Immunostimulatory function of ergothioneine in Tamogi mashroom.PLoS ONE. 12:e0169360
  7. Kataoka, K., Y. Shiraishi, Y. Takeda, S. Sakata, M. Matsumoto, S. Nagano, Y. Nagata, A. Kitanaka, S. Mizuno, H. Tanaka, K. Chiba, Y. Watatani, H. Suzuki, T. Yoshizato, K. Yoshida, M. Sanada, H. Itonaga, Y. Imaizumi, Y. Totoki, W. Munakata, H. Nakamura, N. Hama, K. Shide, Y. Kubuki, T. Hidaka, T. Kameda, K. Masuda, N. Minato, K. Kashiwase, K. Izutsu, A. Takaori-Kondo, Y. Miyazaki, S. Takahashi, T. Shibata, H. Kawamoto, Y. Akatsuka, K. Shimoda, K. Takeuchi, T. Seya, S. Miyano, and S. Ogawa. 2016. Aberrant PD-L1 expression via 3’-UTR disruption in multiple cancers.Nature. 534(7607): 402-406
  8. Takeda, Y., M. Azuma, M. Matsumoto, T. Seya. 2016. Tumor killing efficacy coincides with CD11c up-regulation in antigen-specific CD8+ T cells during Poly(I:C) vaccine immunotherapy.J Exp Clin Cancer Res. 35:143.
  9. Kouwaki T, Fukushima Y, Daito T, Senada T, Yamamoto N, Mifsud EJ, Leong CR, Tsukiyama-Kohara K, Kohara M, Matsumoto M, Seya T, and Oshiumi H. 2016. Exosome RNA Released by Hepatocytes Regulates Innate Immune Responses to Hepatitis B Virus Infection.Front Immunol. 7:335.
  10. Leong, C. R., H. Oshiumi, M.,M.Deng, M. Okamoto, H. Takaki, M. Matsumoto, and T. Seya. 2016. ISG20 inhibits HBV replication by degrading RNA of HBV origin. Oncotarget.7:68179-68193.
  11. Takaki, H., H. Sato, H. Oshiumi, M. Matsumoto, R. Kurata, H. Hikino, T. Saito, and T. Seya. 2016. Cytokine response to eye drop adjuvants in chicken.Microbiol Immunol. 60:511-515.
  12. Takashima, K., Y. Takeda, H. Oshiumi, H. Shime, M. Okabe, M. Ikawa, M. Matsumoto, and T. Seya. 2016. STING in tumor and host cells cooperatively work for NK cell-mediated tumor growth retardation.Biochem Biophys Res Commun. 478:1764-1771.
  13. Funami, K., M. Matsumoto, C. Obuse, and T. Seya. 2016. Proteins specifically interacted with activated TICAM-1.Data Brief. 8:697-699.
  14. Oshiumi,H., T. Kouwaki, and T. Seya. 2016. Accessory factors of cytoplasmic viral RNA sensors required for antiviral innate immune response. Front Immunol. 7: 200

2015年

  1. Leong, C. R., H. Oshiumi, M. Okamoto, M. Azuma, H Takaki, M. Matsumoto, K.Chayama, and T. Seya. 2015. A MAVS/TICAM-1-Independent Interferon-Inducing Pathway Contributes to Regulation of Hepatitis B Virus Replication in the Mouse Hydrodynamic Injection Model. J. Innate Immun. 7: 47-58.
  2. Kasamatsu, J., S. Takahashi, M. Azuma, M. Matsumoto, A. Morii-Sakai, M. Imamura, T. Teshima, A. Takahashi, Y. Hirohashi, T. Torigoe, N. Sato, and T. Seya. 2015. PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice. Immunobiol. 220: 74-82.
  3. Matsumoto, M., M. Tatematsu, F. Nishikawa, M. Azuma, H. Shime, and T. Seya. 2015. Defined TLR3-specific adjuvant that induces NK and cytotoxic T cell activation without significant cytokine production in vivo. Nat Commun. 6:e6280.
  4. Maruyama, A., H. Shime, Y. Takeda, M. Azuma, M. Matsumoto, and T. Seya. 2015. Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signaling. Biochem Biophys Res Commun. 457:445-450.
  5. Funami, K., M. Matsumoto, N. Ishii, M. Tatematsu, Y. Enokizono, F. Inagaki, H. Oshiumi, and T. Seya. 2015. A determinant for inner membrane localization in the TIR domain of TICAM-2: A regulator for TLR4-mediated TICAM-1 signaling. J. Immunol. 195:4456-4465.
  6. Takemura, R., H. Takaki, S. Okada, H. Shime, H. Oshiumi, T. Akazawa, M. Matsumoto, T. Tejima, and T. Seya. 2015. PolyI:C-induced, TLR3/RIP3-dependent necroptosis backs up immune effector-mediated tumor elimination in vivo. Cancer Immunol Res. 3:902-914.
  7. Takashima, K., H. Oshiumi, H. Takaki, M. Matsumoto, and T. Seya. 2015. RIOK-mediated phosphorylation of the MDA5 C-terminal region interferes with MDA5 assembly and attenuates MDA5-mediated antiviral innate immune response. Cell Reports. S2211-1247.
  8. Oshiumi, H., M. Miyashita, M. Okamoto, Y. Morioka, M. Okabe, M. Matsumoto, and T. Seya. 2015. Dual roles of DDX60 in antiviral innate immunity and regulation of DDX60 functions by epidermal growth factor. Cell Reports. 11:1193-1207.
  9. Romanets, O., L. M. Kovalevska, T. Seya, S. P. Sidorenko, and B. Horvat. 2015. Interaction of Measles virus hemagglutinin with CD150-expressing dendritic cells is sufficient to induce immunosuppression. Cell Molec Immunol. 2015 Jun 15.doi:10.1038/cmi.2015.55.
  10. Tatematsu, M., K. Funami, N. Ishii, T. Seya, C. Obuse, M. Matsumoto. 2015. LRRC59 is involved in trafficking of nucleic acid-sensing TLRs from the ER. J Immunol. 195:4933-4942.
  11. [Errortum] Ebihara, T., T. Seya. 2015. Errortum: Identification of a polyIC-inducible membrane protein that participates in dendritic cell-mediated NK cell activation. J Exp Med. 212:1337.
  12. Sato, H., H. Oshiumi, H. Takaki, M. Matsumoto, H. Hikono, and T. Seya. 2015. Evolution of the DEAD box helicase family in the chicken: chicken has no DHX9 orthologue.Microbiol Immunol.59: 633-640.
  13. Seya. T., H. Shime, and M. Matsumoto. 2015. Functional alteration of tumor-infiltrating myeloid cells in RNA adjuvant therapy. Anticancer Res.35: 4385-4392.
  14. Seya, T., Y. Takeda, and M. Matsumoto. 2015. Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia. Oncoimmunol. (in press), 2015.
  15. Leong, C. R., M. Matsumoto, T. Suzuki, H. Oshiumi, and T. Seya. 2015. Nucleic acid sensors involved in the recognition of hepatitis B virus (HBV) in the liver-specific in vivo transfection mouse models-Pattern recognition receptors and sensors for HBV. Med Sciences. 3: 16-24.
  16. Nakai, M., H. Oshiumi, K. Funami, M. Matsumoto, T. Seya and N. Sakamoto. 2015. Interferon (IFN)- in innate immune response during infection with HCV. Sensors15: 27160-27173.
  17. Seya, T., H. Shime, Y. Takeda, M. Tatematsu, K. Takashima, and M. Matsumoto. 2015. Adjuvant for vaccine immunotherapy of cancer – focusing on TLR2 and TLR3 agonists for safe enhancing antitumor immunity. Cancer Sci.Sep 23. doi: 10.1111/cas.12824.
  18. Takaki, H., H. Shime, M. Matsumoto, and T. Seya. 2015. Tumor cell death by pattern-sensing of exogenous RNA: tumor cell TLR3 directly induces necroptosis by polyI:C in vivo,independent of immune effector-mediated tumor shrinkage. Oncoimmunol. (in press)
  19. Takashima, K., H. Oshiumi, T. Seya. 2015. RIOK3 keeps MDA5 inactive.Oncotarget. 6:30423-30424.

2011年～2014年

2006年～2010年

2000年～2005年